SY 1365

Drug Profile

SY 1365

Alternative Names: Cyclin-dependent kinase 7 inhibitors; SY 1365

Latest Information Update: 13 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Syros Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors; Gene expression modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia; Cancer; Ovarian cancer

Most Recent Events

  • 12 May 2017 SY 1365 - Syros is available for licensing as of 12 May 2017. www.syros.com
  • 12 May 2017 Syros plans to initiate a phase I/II clinical trial for Acute myeloid leukaemia and Acute lymphoblastic leukaemia
  • 02 May 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT03134638)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top